Novo Nordisk's (NVO) semaglutide, sold under the brand name Ozempic, helped mitigate alcohol cravings in adults with alcohol use disorder in a clinical trial, researchers said in findings published Wednesday in the medical journal JAMA Psychiatry.
The researchers said results of the randomized trial offer preliminary prospective evidence supporting efficacy of low-dose semaglutide in reducing alcohol cravings, thus justifying further investigation in larger studies.
The trial that sought to evaluate the effects of once-weekly subcutaneous semaglutide on alcohol consumption and cravings involved nine weeks of outpatient treatment, with 48 participants receiving small doses ranging from 0.25 milligram to 1 mg per week.
Novo Nordisk did not immediately reply to MT Newswires' request for comment.
Price: 81.71, Change: -2.04, Percent Change: -2.43
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.